e-Drug3D

1614

RIOCIGUAT

INN
RIOCIGUAT

cas 625115-55-1

CLASS

CARDIOVASCULAR
ANTIHYPERTENSIVE
PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH)
PULMONARY ARTERIAL HYPERTENSION (PAH)
GUANYLATE CYCLASE (SGC) STIMULATOR (RECEPTOR FOR NITRIC OXIDE (NO))

ROUTE (list)

ORAL

ATC code

C02KX05

PK parameters

F 94 PERCENT
VD 30 LITER
Cl 2.6 LITER / HOUR
PPB 95 PERCENT
t1/2 9.5 HOUR

Solubility

IN WATER (4 MILLIGRAM / LITER)

Target

TARGET SOLUBLE GUANYLATE CYCLASE

PDB
8HBF (STRUCTURE OF HUMAN SOLUBLE GUANYLATE CYCLASE IN THE NO+RIO STATE AT 3.1 ANGSTROM)

Ligand code = GZO (link to the list of PDB complexes)

Download experimental 3D coordinates of GZO with added hydrogens

DrugCentral

Guanylate cyclase soluble subunit beta-1 UNIPROT Q02153 GUCY1B3

Download SDF file

Carbamic acid, N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-, methyl ester

Formula:
C20H19FN8O2

Calculated chemical properties:

MW 422.43
NB_atoms 31
XLogP 2.44
PSA 120.113
NB_HD 4
NB_HA 10
fsp3 0.15
Lipinski(0=no;1=yes) 1

FDA
NDA 204819 (pdf not found) INN (RIOCIGUAT) ADEMPAS (BAYER HLTHCARE) APPROVAL= AP YEAR= 2013 NEWMOLECULARENTITY
NDA 211044 (pdf not found) INN (RIOCIGUAT) RIOCIGUAT (TEVA PHARMS USA INC) APPROVAL= TA YEAR= 2022
NDA 211135 (pdf not found) INN (RIOCIGUAT) RIOCIGUAT (MSN) APPROVAL= AP YEAR= 2022